doomed
6 días hace
Home / Finance
Ayr Wellness is selling 4 marijuana stores in Illinois
Doomed
March 11, 2025
Ayr Wellness has signed a letter of intent to sell its four marijuana stores in Illinois because the company doesn’t have the scale to compete over the long term.
“We’re taking a hard look at other markets to make sure we are prioritizing those core markets that will deliver for our business,” Ayr President George DeNardo said during the company’s fourth-quarter and full-year 2024 earnings call.
Asked by MJBizDaily for more details on the pending sale, a company spokesperson said, “None of that information is public at this time.”
Ayr’s decision to sell its four Illinois stores was first reported by Green Market Report.
The MSO will continue to consolidate its facilities in its core markets, said DeNardo, who in January was promoted from chief operating officer to CEO.
Ayr began the consolidation process in 2024 by closing a manufacturing facility in Nevada and subleasing its original medical marijuana cultivation and manufacturing facility in Massachusetts.
The company plans to close a second cultivation facility later this month and consolidate its grow operations into a single facility, DeNardo said.
Meanwhile, Ayr will more than double its flower production when the company’s indoor cultivation facility in Ocala, Florida, is fully operational, according to DeNardo.
Ayr’s stores in Florida account for about 70% of its retail network.
“This facility will complement our existing Gainesville facility directly addressing our current deficit in premium flower production, which is a highly sought-after category by customers,” DeNardo said.
The company also is focused on scaling its business in Ohio, where adult-use sales during the fourth quarter contributed “meaningful increases in both retail and wholesale revenues,” DeNardo said.
Ayr operates four adult-use stores in Ohio and plans to open a fifth store in the state later this month.
Shares of Ayr trade as AYR.A on the Canadian Securities Exchange and AYRWF on the over-the-counter markets.
nilremerlin
4 meses hace
DEA Banner - New Seal 4/29
FOR IMMEDIATE RELEASE
Contact: DEA Media Affairs
(571) 776-2508
Media Advisory
DEA to Hold Hearing on the Rescheduling of Marijuana
WASHINGTON – Formal hearing proceedings regarding the proposed rescheduling of marijuana will begin on December 2, 2024 at 9:30 A.M. ET in the North Courtroom at DEA Headquarters located at 700 Army Navy Drive, Arlington, VA. This preliminary hearing will serve as a procedural day to address legal and logistical issues and discuss future dates for the evidentiary hearing on the merits. No witness testimony will be offered or received at this time.
In-person attendance is limited to designated participants and credentialed members of the media who have received confirmation of their in-person attendance.
WHAT: Commencement of formal hearing proceedings regarding the proposed rescheduling of Marijuana
WHO: Open to designated participants and designated credentialed members of the media.
WHEN: December 2, 2024
9:30 a.m. to 5:00 p.m.
WHERE: DEA Headquarters
700 Army Navy Drive
Arlington, VA 22202
North Courtroom
FOR MEMBERS OF THE PUBLIC: Members of the public will have access to the court sessions virtually at www.DEA.gov/live.
FOR NEWS MEDIA: News media wishing to attend in person must RSVP to DEAPress@dea.gov by 10 a.m. on November 29, 2024. Due to limited capacity, RSVPs will be accepted on a first come, first served basis.
Designated members of the media should arrive no later than 9:00 a.m. on December 2 and follow all security screening procedures. Media credentials are required to be visible while inside DEA Headquarters. Video and audio recordings are not permitted at any time inside the courtroom.
Background:
On May 21, 2024, the Department of Justice proposed to transfer marijuana from Schedule I of the Controlled Substances Act to Schedule III of the CSA, consistent with the view of the Department of Health and Human Services that marijuana has a currently accepted medical use as well as HHS's views about marijuana's abuse potential and level of physical or psychological dependence. The CSA requires that such actions be made through formal rulemaking on the record after opportunity for a hearing. If the transfer to Schedule III is finalized, the regulatory controls applicable to Schedule III controlled substances would apply, as appropriate, along with existing marijuana-specific requirements and any additional controls that might be implemented, including those that might be implemented to meet U.S. treaty obligations. If marijuana is transferred into Schedule III, the manufacture, distribution, dispensing, and possession of marijuana would remain subject to the applicable criminal prohibitions of the CSA. Any drugs containing a substance within the CSA's definition of “marijuana” would also remain subject to the applicable prohibitions in the Federal Food, Drug, and Cosmetic Act. For more information, visit www.DEA.gov.